125892022_web1_125892022-284c559f8de844e88cff84290788d5c2

Bama striving to replace (some of) Waddle’s production

125891930_web1_IMG_6513

Redeemer, Wallenpaupack field hockey winners

By MARILYNN MARCHIONE 
 U.S. government officials are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalized with COVID-19 because it doesn’t seem to be helping them. 
 Independent monitors had paused enrollment in two weeks ago because of a possible safety issue. But on Monday, the National Institute of Allergy and Infectious Diseases, which sponsors the study, said a closer look found no safety problem but a low chance that the drug would prove helpful for hospitalized patients. 
 It is a setback for one of the most promising treatment approaches for COVID-19. President Donald Trump received a similar experimental antibody drug from Regeneron Pharmaceuticals Inc. on an emergency basis when he was sickened with the coronavirus earlier this month.
 In a statement Lilly notes that the government is continuing a separate study testing the antibody drug in mild to moderately ill patients, to try to prevent hospitalization and severe illness. The company also is continuing its own studies testing the drug, which is being developed with the Canadian company AbCellera. 
 Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. The experimental drugs are concentrated versions of one or two specific antibodies that worked best against the coronavirus in lab and animal tests.
 Lilly and Regeneron have asked the U.S. Food and Drug Administration to grant emergency use authorization for their drugs for COVID-19 while late-stage studies continue. Lilly says its request is based on other results that the drug is beneficial.
 ___
 The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Lilly antibody drug fails in a COVID-19 study; others go on